CELADON PHARMACEUTICALS PLC Logo

CELADON PHARMACEUTICALS PLC

Vertically integrated pharma developing cannabis medicines for chronic pain.

CEL | IL

Overview

Corporate Details

ISIN(s):
GB00BDQYGP38
LEI:
213800YXCATORT475807
Country:
United Kingdom
Address:
32-33 COWCROSS STREET, EC1M 6DF LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Celadon Pharmaceuticals PLC is a vertically integrated pharmaceutical company focused on the research, cultivation, manufacturing, and commercial sale of cannabis-based medicines. The company's primary target market is chronic pain, aiming to provide alternatives to traditional treatments. It operates a licensed, 100,000 sq ft, EU-GMP certified facility for the indoor cultivation of high-THC cannabis and the extraction of Active Pharmaceutical Ingredients (API). A key differentiator is its MHRA-conditionally approved clinical trial for chronic pain, which seeks to generate robust data for potential reimbursement by national health services. Founded in 2018, Celadon is also engaged in R&D to generate novel intellectual property and develop a pipeline of prescription medicines for various conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-28 17:10
Post-Annual General Meeting Information
Result of General Meeting
English 20.4 KB
2025-07-02 08:00
Pre-Annual General Meeting Information
Proposed Cancellation
English 99.3 KB
2025-07-01 12:48
Capital/Financing Update
Funding Update
English 10.8 KB
2025-07-01 09:20
Post-Annual General Meeting Information
Result of AGM
English 24.0 KB
2025-06-30 08:00
Report Publication Announcement
Funding and Operational Update, Delay in Results
English 22.5 KB
2025-06-11 08:00
Capital/Financing Update
New Committed Credit Facility
English 14.2 KB
2025-06-06 16:55
Regulatory News Service
Funding Update, Notice of AGM
English 12.1 KB
2025-05-30 19:07
Capital/Financing Update
Funding Update
English 11.3 KB
2025-03-19 08:00
Capital/Financing Update
Funding Update
English 11.8 KB
2025-02-26 14:00
Capital/Financing Update
New Committed Credit Facility
English 15.5 KB
2025-02-12 08:00
Capital/Financing Update
Finance Update
English 10.4 KB
2025-01-31 08:00
Capital/Financing Update
Finance Update
English 10.7 KB
2025-01-16 08:00
Regulatory News Service
Update on Strategic Collaboration
English 13.7 KB
2025-01-02 08:00
Capital/Financing Update
Funding Update
English 10.6 KB
2024-12-20 08:00
Capital/Financing Update
Finance Update
English 10.8 KB

Automate Your Workflow. Get a real-time feed of all CELADON PHARMACEUTICALS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for CELADON PHARMACEUTICALS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden SPRINT
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea 052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan 4888

Talk to a Data Expert

Have a question? We'll get back to you promptly.